Review of The STREAM Study for evaluation of standardised regimens for the treatment of rifampicin-resistant tuberculosis (TB)
The STREAM stage 2 TB study compared two bedaquiline-containing regimens with the previous 9-month STREAM stage 1 regimen study.
Educational Objectives
Educational Aim:
The aim of this article is to provide information about a phase 3, TB trial in seven countries, in individuals aged 15 years or older with rifampicin-resistant tuberculosis and its outcomes.
Editor's comments:
Multidrug-resistant (MDR) or rifampicin-resistant tuberculosis is difficult to treat, and outcomes have been poor in the past. Effective, well tolerated short regimens that are easy to use are urgently needed. Drug resistant tuberculosis is largely missed in Africa, and this threatens prospects to achieve the 2035 targets, therefore urgent efforts are required to confirm the true burden of drug resistant tuberculosis in Africa. Adoption of new tools and drugs is essential if the future targets are to be met as the World Health Organization (WHO) has set targets to end tuberculosis by 2035 and is directing efforts at accelerating the rate of decline, with the expectation of reducing the incidence rate by 90% and mortality by 95% compared to levels in 2015.
Educational Outcomes:
Upon completion of this module practitioners should have a clear understanding of:
- potential future treatment regimens for rifampicin-resistant tuberculosis.
Instructions for this Module
- Read the supplied reading material and complete the quiz that follows;
- You have three attempts to pass the quiz;
- The pass grade is 70%;
- You need to pass the quiz to claim your CPD certificate;
- Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.
If you need any assistance to complete this module, please Contact us